Pfizer (PFE) Cash from Discontinued Operations (2020 - 2022)
Historic Cash from Discontinued Operations for Pfizer (PFE) over the last 9 years, with Q3 2022 value amounting to -$5.0 million.
- Pfizer's Cash from Discontinued Operations fell 12941.18% to -$5.0 million in Q3 2022 from the same period last year, while for Oct 2022 it was -$332.0 million, marking a year-over-year decrease of 11583.97%. This contributed to the annual value of -$343.0 million for FY2021, which is 10887.91% down from last year.
- As of Q3 2022, Pfizer's Cash from Discontinued Operations stood at -$5.0 million, which was down 12941.18% from -$327.0 million recorded in Q4 2021.
- Pfizer's Cash from Discontinued Operations' 5-year high stood at $2.4 billion during Q3 2020, with a 5-year trough of -$327.0 million in Q4 2021.
- Over the past 3 years, Pfizer's median Cash from Discontinued Operations value was $17.0 million (recorded in 2021), while the average stood at $564.4 million.
- Per our database at Business Quant, Pfizer's Cash from Discontinued Operations plummeted by 9807.26% in 2021 and then crashed by 12941.18% in 2022.
- Quarter analysis of 3 years shows Pfizer's Cash from Discontinued Operations stood at $2.4 billion in 2020, then plummeted by 113.55% to -$327.0 million in 2021, then skyrocketed by 98.47% to -$5.0 million in 2022.
- Its Cash from Discontinued Operations stands at -$5.0 million for Q3 2022, versus -$327.0 million for Q4 2021 and $17.0 million for Q3 2021.